SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita miceVolker Vallon, Timo Rieg, Joseph Satriano et al.|American Journal of Physiology-Renal Physiology|2013Cited by 481
Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic miceTimo Rieg, Volker Vallon, Maria Gerasimova et al.|American Journal of Physiology-Renal Physiology|2012Cited by 158
Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retentionTakahiro Masuda, Volker Vallon, Yiling Fu et al.|American Journal of Physiology-Endocrinology and Metabolism|2013Cited by 16
What makes SGLT2 inhibition so effective in lowering blood glucose in diabetes? (689.5)Maria Gerasimova, Volker Vallon, Michael Rose et al.|The FASEB Journal|2014Cited by 1
Dipeptidyl peptidase‐4 inhibitor lowers PPARγ agonist‐induced body weight gain by affecting food intake, fat mass and beige/brown fat but not fluid retention (1160.9)Yiling Fu, Volker Vallon, Ariel E. Feldstein et al.|The FASEB Journal|2014Cited by 1